A proatherogenic role for cGMP-dependent protein kinase in vascular smooth muscle cells

Wolfsgruber, Wiebke; Feil, Susanne; Brummer, Sabine; Kuppinger, Oliver; Hofmann, Franz; Feil, Robert

doi:10.1073/pnas.1936024100

Cited by 78 publications

(80 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These observations identify a function of cGKI signaling in the regulation of erythrocyte survival and support the emerging concept that pathways via NO, cGMP, and cGKI stimulate growth and survival in a number of cell types in vivo (55)(56)(57)(58).…”

Section: Figsupporting

confidence: 74%

Anemia and splenomegaly in cGKI-deficient mice

Föller

Feil²,

Ghoreschi³

et al. 2008

Proc. Natl. Acad. Sci. U.S.A.

Self Cite

133

115

View full text Add to dashboard Cite

To explore the functional significance of cGMP-dependent protein kinase type I (cGKI) in the regulation of erythrocyte survival, gene-targeted mice lacking cGKI were compared with their control littermates. By the age of 10 weeks, cGKI-deficient mice exhibited pronounced anemia and splenomegaly. Compared with control mice, the cGKI mutants had significantly lower red blood cell count, packed cell volume, and hemoglobin concentration. Anemia was associated with a higher reticulocyte number and an increase of plasma erythropoietin concentration. The spleens of cGKI mutant mice were massively enlarged and contained a higher fraction of Ter119 ؉ erythroid cells, whereas the relative proportion of leukocyte subpopulations was not changed. The Ter119 ؉ cGKI-deficient splenocytes showed a marked increase in annexin V binding, pointing to phosphatidylserine (PS) exposure at the outer membrane leaflet, a hallmark of suicidal erythrocyte death or eryptosis. Compared with control erythrocytes, cGKI-deficient erythrocytes exhibited in vitro a higher cytosolic Ca 2؉ concentration, a known trigger of eryptosis, and showed increased PS exposure, which was paralleled by a faster clearance in vivo. Together, these results identify a role of cGKI as mediator of erythrocyte survival and extend the emerging concept that cGMP/cGKI signaling has an antiapoptotic/prosurvival function in a number of cell types in vivo.apoptosis ͉ Ca2ϩ channels ͉ phosphatidylserine ͉ spleen N itric oxide (NO) has been shown to be a powerful regulator of cell survival (1, 2). Depending on the source or concentration of NO and the influence of additional regulators, NO may stimulate or inhibit apoptosis (3). NO exerts its effects in part through S-nitrosylation of target proteins. However, the effect of NO donors on Ca 2ϩ -induced phosphatidylserine (PS) exposure, a hallmark of apoptosis, could be mimicked by cGMP analogs (4), suggesting the involvement of soluble guanylyl cyclase, cGMP, and cGMP-dependent protein kinase type I (cGKI), a well known signaling cascade downstream of NO (5, 6).Recent studies indicated that erythroid cells possess a functional NO/cGMP pathway (7-9), which may be involved in the regulation of eryptosis, the suicidal death of erythrocytes (10). Erythrocyte cGMP production might also be stimulated by NO generated in the endothelium. The cGKI can also be activated independent of cGMP in response to oxidative stress (11). Eryptosis may follow osmotic shock, energy depletion, and oxidative stress (10), which activate Ca 2ϩ -permeable cation channels (12). Subsequent Ca 2ϩ entry leads to activation of Ca 2ϩ -sensitive K ϩ channels, exit of KCl with osmotically obliged water, and thus cell shrinkage (13). In addition, Ca 2ϩ entry triggers Ca 2ϩ -sensitive scrambling of the cell membrane (14, 15) with subsequent exposure of PS at the erythrocyte surface (12). Cell membrane scrambling may further be triggered by ceramide (16) and activation of protein kinase C (17). PS-exposing erythrocytes bind to PS receptors (18) and are recognized, ...

show abstract

Section: Figsupporting

confidence: 74%

Anemia and splenomegaly in cGKI-deficient mice

Föller

Feil²,

Ghoreschi³

et al. 2008

Proc. Natl. Acad. Sci. U.S.A.

Self Cite

133

115

View full text Add to dashboard Cite

show abstract

“…cell number, relative cell number. (31)(32)(33). Therefore, it was tested whether Rp-PET could inhibit cGMP/cGKI-stimulated VSMC growth and phosphorylation of VASP.…”

Section: Resultsmentioning

confidence: 99%

The Commonly Used cGMP-dependent Protein Kinase Type I (cGKI) Inhibitor Rp-8-Br-PET-cGMPS Can Activate cGKI in Vitro and in Intact Cells

Valtcheva

Nestorov

Beck

et al. 2009

Journal of Biological Chemistry

Self Cite

View full text Add to dashboard Cite

cGMP is a cyclic-nucleotide second messenger with multiple targets and functions. Small-molecule modulators of cGMP generators and effectors are important biochemical tools as well as established and prospective drugs for the treatment of human diseases, such as erectile dysfunction, pulmonary hypertension, and various cardiovascular disorders (1-3). cGMP is generated by nitric oxide-or natriuretic peptide-stimulated guanylyl cyclases and can bind to and modulate the activity of at least three classes of cGMP effector proteins: cyclic nucleotide-hydrolyzing phosphodiesterases (PDEs), 2 cyclic nucleotide-gated cation channels, and cGMP-dependent protein kinases (cGKs, also known as protein kinase G or PKG) (4).Based on pharmacological and genetic studies, the cGK type I (cGKI) is considered the major mediator of cGMP signaling in many tissues including the cardiovascular system (5-8). The mammalian cGKI is a cytosolic Ser/Thr protein kinase comprising an N-terminal regulatory domain with two cGMPbinding sites and a C-terminal catalytic domain. It exists in two isoforms termed cGKI␣ and cGKI␤. The isozymes have identical cGMP-binding sites and catalytic domains but differ in their N-terminal ϳ100 amino acids, which contribute to homodimerization, sensitivity to cGMP activation, and interaction with anchoring and substrate proteins. Recent in vivo studies with transgenic mice demonstrated that both isoforms can induce smooth muscle relaxation and vasodilation (9), but the respective molecular mechanisms behind these effects are controversial (6, 10). Similarly, opposing effects of cGMP/cGKI signaling have been reported on the growth and phenotype of vascular smooth muscle cells (VSMCs) (11,12). The inconsistency of the results concerning the function of cGKI might in part be related to unexpected effects of the pharmacological cGKI activators and inhibitors that are commonly used to distinguish between cGKI-dependent and cGKI-independent signaling. For instance, cGMP analogues can bind to multiple * This work was supported by grants from the Deutsche Forschungsgemeinschaft. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. 2 The abbreviations used are: PDE, phosphodiesterase; cGKI, cGMP-dependent protein kinase type I; PET, 8-Br-PET-cGMP; Rp-PET, Rp-8-Br-PETcGMPS; 8-Br-PET-cGMP, ␤-phenyl-1,N 2 -etheno-8-bromoguanosine-3Ј,5Ј-cyclic monophosphate; Rp-8-pCPT-cGMPS, 8-(4-chlorophenylthio)-guanosine-3Ј, 5Ј-cyclic monophosphorothioate, Rp-isomer; Rp-8-Br-PET-cGMPS, ␤-phenyl-1,N 2 -etheno-8-bromoguanosine-3Ј,5Ј-cyclic monophosphorothioate, Rp-isomer; VASP, vasodilator-stimulated phosphoprotein; VSMC, vascular smooth muscle cell; MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; CFP, cyan fluorescent protein; YFP, yellow fluorescent protein; ESI-MS, electrospray ionization-mass spectrometry; ...

show abstract

“…In addition, studies have shown that NO promotes Akt phosphorylation via cGMP production in vascular smooth muscle cells (26), which could provide a link between shear stress on the endothelium and Akt phosphorylation in smooth muscle. Abolishing NO production by L-NAME caused decreased Akt phosphorylation in WT but not KO portal veins, despite a probably higher NO production in KO portal veins.…”

Section: Discussionmentioning

confidence: 99%

Differential dependence of stretch and shear stress signaling on caveolin-1 in the vascular wall

Albinsson¹,

Nordström²,

Swärd³

et al. 2008

American Journal of Physiology-Cell Physiology

View full text Add to dashboard Cite

The role of caveolae in stretch- versus flow-induced vascular responses was investigated using caveolin 1-deficient [knockout (KO)] mice. Portal veins were stretched longitudinally for 5 min (acute) or 72 h (organ culture). Basal ERK1/2 and Akt phosphorylation were increased in organ-cultured KO veins, as were protein synthesis and vessel wall cross sections. Stretch stimulated acute phosphorylation of ERK1/2 and long-term phosphorylation of focal adhesion kinase (FAK) and cofilin but did not affect Akt phosphorylation. Protein synthesis, and particularly synthesis of smooth muscle differentiation markers, was increased by stretch. These effects did not differ in portal veins from KO and control mice, which also showed the same contractile response to membrane depolarization and inhibition by the Rho kinase inhibitor Y-27632. KO carotid arteries had increased wall cross sections and responded to pressurization (120 mmHg) for 1 h with increased ERK1/2 but not Akt phosphorylation, similar to control arteries. Shear stress by flow for 15 min, on the other hand, increased phosphorylation of Akt in carotids from control but not KO mice. In conclusion, caveolin 1 contributes to low basal ERK1/2 and Akt activity and is required for Akt-dependent signals in response to shear stress (flow) but is not essential for trophic effects of stretch (pressure) in the vascular wall.

show abstract

A proatherogenic role for cGMP-dependent protein kinase in vascular smooth muscle cells

Cited by 78 publications

References 50 publications

Anemia and splenomegaly in cGKI-deficient mice

Anemia and splenomegaly in cGKI-deficient mice

The Commonly Used cGMP-dependent Protein Kinase Type I (cGKI) Inhibitor Rp-8-Br-PET-cGMPS Can Activate cGKI in Vitro and in Intact Cells

Differential dependence of stretch and shear stress signaling on caveolin-1 in the vascular wall

Contact Info

Product

Resources

About